U

Urteste SA
WSE:URT

Watchlist Manager
Urteste SA
WSE:URT
Watchlist
Price: 42.5 PLN 8.97% Market Closed
Market Cap: 59.9m PLN

Urteste SA
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Urteste SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
U
Urteste SA
WSE:URT
Cash from Operating Activities
-zł5.5m
CAGR 3-Years
-30%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Cash from Operating Activities
-zł40.5m
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
R
Read Gene SA
WSE:RDG
Cash from Operating Activities
zł2m
CAGR 3-Years
32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genomed SA
WSE:GEN
Cash from Operating Activities
zł1.6m
CAGR 3-Years
-9%
CAGR 5-Years
11%
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Cash from Operating Activities
zł32.5m
CAGR 3-Years
-19%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Cash from Operating Activities
zł1.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Urteste SA
Glance View

Market Cap
59.9m PLN
Industry
Biotechnology

Urteste SA specializes in the development of technology that allows the detection of cancers at early stages of their development. The company is headquartered in Gdansk, Woj. Pomorskie. The company went IPO on 2021-10-27. The firm operates in the field of medical devices for in vitro application in the field of cancer diagnostics. The technology developed by the Company involves the detection of cancer by measuring the activity of enzymes in a urine sample, using diagnostic tests that enable the detection of common cancers in their early stages. The firm offers tests for the detection of cancers such as, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, kidney cancer, liver cancer, biliary tract cancer, stomach cancer, esophageal cancer, ovarian cancer, endometrial cancer, breast cancer, leukemia, lymphoma, glioma.

URT Intrinsic Value
0.27 PLN
Overvaluation 99%
Intrinsic Value
Price
U

See Also

What is Urteste SA's Cash from Operating Activities?
Cash from Operating Activities
-5.5m PLN

Based on the financial report for Dec 31, 2024, Urteste SA's Cash from Operating Activities amounts to -5.5m PLN.

What is Urteste SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-69%

Over the last year, the Cash from Operating Activities growth was -3%. The average annual Cash from Operating Activities growth rates for Urteste SA have been -30% over the past three years , -69% over the past five years .

Back to Top